Pfizer Inc. (NYSE:PFE) Stock Holdings Lowered by NewEdge Wealth LLC

NewEdge Wealth LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 27.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,474 shares of the biopharmaceutical company’s stock after selling 24,229 shares during the quarter. NewEdge Wealth LLC’s holdings in Pfizer were worth $1,856,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Moneta Group Investment Advisors LLC raised its holdings in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Norges Bank acquired a new stake in shares of Pfizer during the fourth quarter valued at approximately $3,150,472,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after acquiring an additional 9,393,992 shares during the period. Morgan Stanley raised its holdings in shares of Pfizer by 10.3% during the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after acquiring an additional 7,419,929 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Pfizer during the first quarter valued at approximately $311,238,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

NYSE PFE opened at $25.86 on Monday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a fifty day simple moving average of $27.28 and a 200 day simple moving average of $28.88. The company has a market cap of $146.43 billion, a P/E ratio of 71.83, a P/E/G ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $41.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 1st. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.